Clinical trial
Post-authorisation Observational Study for the Assessment of Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance <50 mL/Min/1.73 m2 (CrCl <50 mL/Min/1.73 m2)
NCT02849444 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-authorisation Observational Study for the Assessment of Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance <50 mL/Min/1.73 m2 (CrCl <50 mL/Min/1.73 m2)
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 23, 2012
- Completion date
- December 10, 2020
- Enrollment
- 326 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.